Patent Classification

Drug Delivery System, Antigen/Vaccine/Hormone/Antibody

1. Adjuvant systems and vaccines
    
2. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
    
3. Vaccine against cancer diseases that are associated with the her-2/neu oncogene
    
4. Regulated antigen delivery system (RADS)
    
5. Membrane virus host range mutations and their uses as vaccine substrates
    
6. Vaccine compositions including chitosan for intranasal administration and use thereof
    
7. Molecular vaccine linking intercellular spreading protein to an antigen
    
8. Influenza vaccine composition
    
9. Cationic lipid-mediated enhancement of nucleic acid immunization of cats
    
10. Nanoemulsion vaccines
     
11. Nanoparticle vaccines
     
12. DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
     
13. Mucosal DTPa vaccines
     
14. Live genetically attenuated malaria vaccine
     
15. Polynucleotide encoding a mutated HIV gp41 polypeptide
     
16. Tumor vaccines
     
17. Method of removing endotoxin from vaccines
     
18. Enveloped virus vaccine and method for production
     
19. Anti-CD40 monoclonal antibody
     
20. Peptide-based vaccine for influenza
     
21. Attaching substances to micro-organisms
     
22. Process for preparing conjugate vaccines and the conjugate vaccines
     
23. Histamine receptor antibody
     
24. Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
     
25. Adjuvant-containing vaccines
     
26. Attenuated human rotavirus vaccine
     
27. Plasmid maintenance system for antigen delivery
     
28. Urogenital or anorectal, transmucosal vaccine delivery system
     
29. Methods for enhancing the production of viral vaccines in cell culture
     
30. Streptococcus pneumoniae proteins and vaccines
     
31. Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
     
32. Multivalent antibody constructs
     
33. Production of humanized antibodies in transgenic animals
     
34. Immunstimulating lipid formulation
     
35. Live genetically attenuated malaria vaccine
     
36. Microfluidized oil-in-water emulsions and vaccine compositions
     
37. Smallpox vaccine
     
38. Attenuated Salmonella strain used as a vehicle for oral immunization
     
39. Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
     
40. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
     
41. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
     
42. Modified vaccinia virus ankara for the vaccination of neonates
     
43. Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
     
44. Inactivated respiratory syncytial viral vaccines
     
45. Nontoxic mucosal adjuvant
     
46. Hybrid LT-A/CT-B holotoxin for use as an adjuvant
     
47. Live vaccines for allergy treatment
     
48. Glucosyltransferase immunogens
     
49. Inactivated influenza virus vaccine for nasal or oral application
     
50. Adjuvant for transcutaneous immunization
     
51. Method for generating influenza viruses and vaccines
     
52. Immunostimulatory oligonucleotides and uses thereof
     
53. DNA vaccination for treatment of autoimmune disease
     
54. Mycobacterium tuberculosis immunizationg
     
55. Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
     
56. Anti-sepsis conjugate vaccine
     
57. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
     
58. Melanoma vaccine and methods of making and using same
     
59. Control of acidosis
     
60. Method for producing monoclonal antibodies
     
61. Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences
     
62. Hepatitis A vaccines
     
63. Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
     
64. Vaccine for the prevention of bacterial infection of the bovine mammary gland
     
65. Vaccine immunotherapy for immune suppressed patients
     
66. Avian pneumovirus vaccine
     
67. Process for producing humanized chimera antibody
     
68. Predictive assay for immune response
     
69. Oral vaccinia formulation
     
70. Polysaccharide-polypeptide conjugate
     
71. Vaccines absorbable by the transmucosal way
     
72. Monoclonal antibodies with reduced immunogenicity
     
73. Multi-stage cascade boosting vaccine
     
74. Vaccine composition comprising iron phosphate as vaccine adjuvant
     
75. Lawsonia intracellularis vaccine
     
76. Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
     
77. Compositions for microencapsulation of antigens for use as vaccines
     
78. Feline calicivirus genes and vaccines in particular recombinant vaccines
     
79. Coccidial vaccine and methods of making and using same
     
80. Vaccines containing attenuated bacteria
     
81. Lyme disease vaccines
     
82. Vaccine against mumps containing a jeryl-lynn virus strain
     
83. Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
     
84. Method for the isolation of polysaccharides
     
85. Formalin-treated human papillomavirus L1 protein vaccine
     
86. Streptococcus pneumoniae proteins and vaccines
     
87. Freeze-dried hepatitis A attenuated live vaccine and its stabilizer
     
88. Nucleic acid constructs
     
89. Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
     
90. Dermatomycosis vaccine
     
91. Vaccine formulations
     
92. Production method of recombinant rotavirus structural proteins and vaccine composition
     
93. Plant lectins as mucosal adjuvants
     
94. Inactivated influenza virus vaccine for nasal or oral application
     
95. Vaccines against Escherichia coli O157 infection
     
96. Vaccines containing ribavirin and methods of use thereof
     
97. Use of microparticles combined with submicron oil-in-water emulsions
     
98. Methods and interferon deficient substrates for the propagation of viruses
     
99. Plasmid-based vaccine for treating atherosclerosis
     
100. Method for the preservation of biologically-active material
      
101. Pneumococcal protein homologs and fragments for vaccines
      
102. Compositions and methods for generating chimeric heteromultimers
      
103. Recombinant multivalent malarial vaccine against Plasmodium falciparum
      
104. Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
      
105. Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
      
106. Multicomponent meningococcal vaccine
      
107. Vectors and methods for immunization or therapeutic protocols
      
108. Polynucleotide vaccine formula in particular against bovine respiratory pathology
      
109. Adjuvants for use in vaccines
      
110. Recombinant parainfluenza virus expression system and vaccines
      
111. Over-expressing homologous antigen vaccine and a method of making the same
      
112. Cellular vaccines and immunotherapeutics and methods for their preparation
      
113. Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
      
114. Method of delivering antigens for vaccination with a live vector
      
115. Method for making humanized antibodies
      
116. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
      
117. Adjuvant for a vaccine composition
      
118. Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
      
119. Heat shock protein-based vaccines and immunotherapies
      
120. Anthrax vaccine
      
121. Live attenuated bacteria for use in a vaccine
      
122. Immunogenic formulations comprising oil bodies
      
123. Fibrocyte-base vaccine formulations
      
124. Adjuvant comprising a lipopolysaccharide antagonist
      
125. Attenuated microorganisms for the treatment of infection
      
126. Enterococcus antigens and vaccines
      
127. Vaccine against lipopolysaccharide core
      
128. Method of making microencapsulated DNA for vaccination and gene therapy
      
129. Proteosome influenza vaccine
      
130. Peptide-based vaccine for influenza
      
131. Method for generating genetically altered antigens
      
132. Surface receptor antigen vaccines
      
133. Smallpox vaccine
      
134. Heat shock protein-based vaccines and immunotherapies
      
135. Compositions and methods for identifying antigens which elicit an immune response
      
136. Noninvasive genetic immunization, expression products therefrom, and uses thereof
      
137. Vaccination by topical application of genetic vectors
      
138. HIV vaccine
      
139. Methods for vaccination and vaccines therefor
      
140. Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
      
141. Methods for enhancing the production of viral vaccines in cell culture
      
142. Adjuvanted vaccine which is substantially free of non-host albumin
      
143. Hepatitus A virus vaccines
      
144. Invaplex from gram negative bacteria, method of purification and methods of use
      
145. Methods for enhancing the production of viral vaccines in cell culture
      
146. Tuberculosis vaccine
      
147. Stratified and cryogenically stored vaccines, process for their preparation
      
148. Microencapsulated DNA for vaccination and gene therapy
      
149. Methods for enhancement of protective immune responses
      
150. Serum-free, low-protein media for rotavirus vaccine production
      
151. Method for the development of an HIV vaccine
      
152. Adjuvant combinations for immunization composition and vaccines
      
153. Helper-free rescue of recombinant negative strand RNA virus
      
154. Inactivated influenza virus vaccine for nasal or oral application
      
155. Herpes simplex virus VP22 vaccines and methods of use
      
156. DNA immunization against chlamydia infection
      
157. Prophylactic and therapeutic monoclonal antibodies
      
158. Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
      
159. Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
      
160. Peptide immunogens for vaccination against and treatment of allergy
      
161. Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
162. Conjugate vaccine for nontypeable Haemophilus influenzae
      
163. Influenza vaccine
      
164. Avian pneumovirus vaccine
      
165. Rotavirus subunit vaccine
      
166. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
      
167. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
      
168. Malaria vaccine
      
169. Stabilizing diluent for polypeptides and antigens
      
170. Temperature sensitive plasmids of P. haemolytica
      
171. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
      
172. Antibody specific for H4-1BB
      
173. Chemokine-tumor antigen fusion proteins as cancer vaccines
      
174. DNA vaccines against poxviruses
      
175. Vaccine compositions for mucosal delivery
      
176. Vaccines for the protection of cattle from psoroptic scabies
      
177. Artificial proteoglycans
      
178. Antigen carbohydrate compounds and their use in immunotherapy
      
179. Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
      
180. Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
      
181. Vaccine against mycobacterial infections
      
182. Live vaccine constituting minor risk for humans
      
183. Oral delivery of nucleic acid vaccines by particulate complexes
      
184. Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
      
185. DNA vaccine and methods for its use
      
186. Method to produce inactivated w/o emulsion adjuvated vaccines
      
187. Therapeutic using a bispecific antibody
      
188. Methods to improve immunogenicity of antigens and specificity of antibodies
      
189. Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
      
190. Method for making humanized antibodies
      
191. Method of preservation of vaccines with polybiguanide
      
192. Vaccine compositions including chitosan for intranasal administration and use thereof
      
193. Influenza virus vaccine composition
      
194. Caulobacter LPS immunoadjuvants
      
195. Parapoxviruses containing foreign DNA, their production and their use in vaccines
      
196. Immunopotentiating formulations for vaccinal use
      
197. NANBV diagnostics and vaccines
      
198. Adjuvants for vaccines
      
199. Anti-cancer vaccine
      
200. Method of specifying vaccine components for viral quasispecies
      
201. Vaccine adjuvants
      
202. Streptococcus gordonii strains resistant to fluorodeoxyuridine
      
203. Production of virus and purification of viral envelope proteins for vaccine use
      
204. Staphylococcus aureus antigen-containing whole cell vaccine
      
205. Formulations of recombinant papillomavirus vaccines
      
206. Use of mCRP to enhance immune responses
      
207. Transdermal, hormone-delivering therapeutic system
      
208. Recombinant mycobacterial vaccine
      
209. Method of making microencapsulated DNA for vaccination and gene therapy
      
210. HIV-vaccines
      
211. DNA vaccines against tick-borne flaviviruses
      
212. Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines
      
213. Concentrated antibody preparation
      
214. Compositions for preserving haptenized tumor cells for use in vaccines
      
215. Method of using mouse model for evaluation of HIV vaccines
      
216. Single-chain forms of the glycoprotein hormone quartet
      
217. Method of affinity cross-linking biologically active immunogenic peptides to antibodies
      
218. Multivalent and multispecific antigen-binding protein
      
219. DNA immunization against chlamydia infection
      
220. Recombinant immunogenic actinomycetale
      
221. Live in ovo vaccine
      
222. Oral administration of pneumococcal antigens
      
223. Vaccine compositions and methods of modulating immune responses
      
224. Adjuvant incorporation into antigen carrying cells: compositions and methods
      
225. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
      
226. Method for the separation and purification of immunoglobulins
      
227. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
      
228. Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine
      
229. Oral immunization with transgenic plants
      
230. Complex of human growth hormone and zinc
      
231. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
      
232. Cross-protective rotavirus vaccine
      
233. Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein
      
234. DNA based vaccination of fish
      
235. Vaccine delivery system
      
236. Synthetic peptides for rubella vaccine
      
237. Process for the production of vaccines and their use
      
238. Synthetic peptides and vaccines comprising same
      
239. Multiassay method for determining the concentrations of antigens and interferants
      
240. Heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
241. DNA vaccines against rotavirus infections
      
242. Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
      
243. Soluble herpesvirus glycoprotein complex vaccine
      
244. Vaccine adjuvant and vaccine
      
245. Human/simian chimeric hepatitis A virus vaccine
      
246. Influenza vaccine compositions
      
247. Helicobacter pylori proteins useful for vaccines and diagnostics
      
248. Wet granulation formulation of a growth hormone secretagogue
      
249. Hepatitis B surface antigen vaccine
      
250. DNA vaccines for eliciting a mucosal immune response
      
251. Oral vaccines
      
252. Vaginal suppository vaccine for urogenital infections
      
253. Coccidiosis poultry vaccine
      
254. Vaccine for induction of immunity to malaria
      
255. Vaccine adjuvant and vaccine
      
256. Multicomponent clostridial vaccines using saponin adjuvants
      
257. Vaccine adjuvant for immunotherapy of melanoma
      
258. Pulmonary delivery of active fragments of parathyroid hormone
      
259. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
      
260. Hepatitis B surface antigen vaccine
      
261. RNA respiratory syncytial virus vaccines
      
262. Stabilized thyroid hormone preparations and methods of making same
      
263. Stabilizers for lyophilized mumps vaccines
      
264. Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
      
265. Composition for sustained release of human growth hormone
      
266. Vaccines for equine influenza
      
267. HIV envelope polypeptides
      
268. Stabilized live vaccine
      
269. Vaccine
      
270. Intestinal protozoal vaccines
      
271. Vaccines expressed in plants
      
272. Mucosal immunogens for novel vaccines
      
273. Mucosal administration of pneumococcal antigens
      
274. Method for producing a bacterial vaccine and novel vaccines produced thereby
      
275. Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
      
276. Subunit respiratory syncytial virus vaccine preparation
      
277. Pharmaceuticals based on papillomaviruses
      
278. Pharmaceutical preparation containing human growth hormone
      
279. Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
      
280. Oral administration of pneumococcal antigens
      
281. Polymeric lamellar substrate particles for drug delivery
      
282. Pharmaceutical formulation
      
283. Self-adjuvanting peptide vaccine delivery system and production thereof
      
284. Stabilized live vaccine
      
285. Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
      
286. Compositions for the delivery of antigens
      
287. Submicron emulsions as vaccine adjuvants